Why the study?
Does bupivacaine or its metabolite pipecoloxylidide inhibit human platelet aggregation in vitro?
Population
Human platelets in vitro
Design
Preclinical
Authors
Loading...
Bupivacaine inhibits platelet aggregation only at supra-clinical concentrations in vitro without metabolite effect; leaves open mechanisms of any delayed in vivo activity.
Does bupivacaine or its metabolite pipecoloxylidide inhibit human platelet aggregation in vitro?
Bupivacaine inhibits platelet aggregation only at supra-clinical concentrations, and its metabolite pipecoloxylidide has no effect, suggesting the delayed in vivo antiplatelet effect is not due to this metabolite.
Odoom et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: